CRSP
Price
$64.76
Change
-$1.30 (-1.97%)
Updated
Jul 25 closing price
Capitalization
5.59B
15 days until earnings call
EDIT
Price
$3.15
Change
-$0.11 (-3.37%)
Updated
Jul 25 closing price
Capitalization
263.7M
3 days until earnings call
Interact to see
Advertisement

CRSP vs EDIT

Header iconCRSP vs EDIT Comparison
Open Charts CRSP vs EDITBanner chart's image
CRISPR Therapeutics AG
Price$64.76
Change-$1.30 (-1.97%)
Volume$2.91M
Capitalization5.59B
Editas Medicine
Price$3.15
Change-$0.11 (-3.37%)
Volume$1.28M
Capitalization263.7M
CRSP vs EDIT Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. EDIT commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (CRSP: $64.76 vs. EDIT: $3.15)
Brand notoriety: CRSP and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 86% vs. EDIT: 47%
Market capitalization -- CRSP: $5.59B vs. EDIT: $263.7M
CRSP [@Biotechnology] is valued at $5.59B. EDIT’s [@Biotechnology] market capitalization is $263.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than EDIT.

Price Growth

CRSP (@Biotechnology) experienced а -0.57% price change this week, while EDIT (@Biotechnology) price change was +14.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.59B) has a higher market cap than EDIT($264M). EDIT YTD gains are higher at: 148.032 vs. CRSP (64.533). EDIT has higher annual earnings (EBITDA): -244.52M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. EDIT (221M). EDIT has less debt than CRSP: EDIT (31.1M) vs CRSP (219M). EDIT (35.8M) and CRSP (35M) have equivalent revenues.
CRSPEDITCRSP / EDIT
Capitalization5.59B264M2,119%
EBITDA-455.24M-244.52M186%
Gain YTD64.533148.03244%
P/E RatioN/AN/A-
Revenue35M35.8M98%
Total Cash1.86B221M839%
Total Debt219M31.1M704%
FUNDAMENTALS RATINGS
CRSP vs EDIT: Fundamental Ratings
CRSP
EDIT
OUTLOOK RATING
1..100
8988
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (43) in the Biotechnology industry is in the same range as CRSP (68). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as EDIT (99). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as CRSP (37). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPEDIT
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFTDX13.350.09
+0.68%
Allspring Innovation Fund - Class Admin
ACGMX23.050.13
+0.57%
Invesco Growth and Income Y
JCAVX9.820.04
+0.41%
JHFunds2 Capital Appreciation Value NAV
RFNBX89.090.27
+0.30%
American Funds Fundamental Invs R2
MKEFX23.00-0.02
-0.09%
BlackRock International Select Eq K

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-1.97%
BEAM - CRSP
72%
Closely correlated
+3.68%
RXRX - CRSP
70%
Closely correlated
+3.67%
NTLA - CRSP
65%
Loosely correlated
+6.38%
CRBU - CRSP
63%
Loosely correlated
-3.80%
ALLO - CRSP
62%
Loosely correlated
-0.66%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-3.37%
CRSP - EDIT
53%
Loosely correlated
-1.97%
NTLA - EDIT
49%
Loosely correlated
+6.38%
RXRX - EDIT
48%
Loosely correlated
+3.67%
PRME - EDIT
47%
Loosely correlated
-3.22%
SLDB - EDIT
47%
Loosely correlated
+4.79%
More